Agilus Diagnostics Limited IPO is fully book build issue and total IPO size is ₹null crores. The entire share offering is an offer for sale of 14233964 shares.
The dates for the Agilus Diagnostics Limited IPO have not been announced yet. The allotment process is expected to be finalized by [.].
The Agilus Diagnostics Limited IPO is scheduled to list on BSE, NSE, with a listing date of [.]. The price band for the Agilus Diagnostics Limited IPO has not been announced yet.
Registrar for this IPO is Kfin Technologies Limited and lead managers for Agilus Diagnostics Limited IPO are Icici Securities Limited, Axis Capital Limited, Citigroup Global Markets India Private Limited.
IPO Schedule
| IPO Open Date | - |
|---|---|
| IPO Close Date | - |
| IPO Allotment Date | - |
| Refund Initiation | - |
| Share credit in Demat | - |
| Listing Date | - |
Key Details
| Price Band | TBA |
|---|---|
| Lot Size | TBA |
| Face Value | ₹10 Per Equity Share |
| Total Issue Size | 14,233,964 Shares |
| Fresh Issue | - |
| OFS Issue | 14,233,964 Shares |
| Issue Type | Offer for Sale |
| Listing At | BSE, NSE |
Share Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB | 50% |
| Retail | 35% |
| NII/HNI | 15% |
About Agilus Diagnostics Limited Company
Agilus Diagnostics, the largest diagnostics service provider in India by number of labs, and second largest in terms of revenue from operations as of Fiscal 2023, offers a comprehensive range of diagnostics testing services. With a network of 413 laboratories, including 43 NABL-accredited labs, it serves 1.66 crore patients and performs 3.91 crore tests annually.
The company operates on a hub-and-spoke model across 25 states and 5 union territories, supported by an integrated system for efficient operations. Agilus boasts a diverse service portfolio of over 3,600 tests including routine and specialized diagnostics, wellness packages, and hospital lab management.
With a focus on customer centricity, Agilus provides an omni-channel experience through its laboratories, mobile app, and website. In Fiscal 2023, the company reported a revenue from operations of ₹134.75 crore. B2C operations generated ₹73.18 crore, accounting for 54.31% of revenue, while the B2B segment contributed ₹61.57 crore, representing 45.69%.
Agilus Diagnostics Limited Financial Details
| Period Ended | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 |
|---|---|---|---|
| Assets | 2418.74 | 2279.96 | 1586.31 |
| Revenue | 1347.46 | 1604.91 | 1035.07 |
| Profit After Tax | 116.64 | 554.71 | 131.25 |
| Net Worth | 1945.58 | 1866.15 | 1311.38 |
| Reserves and Surplus | 1867.15 | 1787.73 | 1232.96 |
| Total Borrowing | 28.29 | 22.51 | 12.53 |
₹ In Crore
Key Performance Indicator
| Basic EPS (in ₹) | Return on Net Worth (RoNW) | Net Asset Value (NAV) | Debt-Equity Ratio | Return on Equity (ROE) | Return on Capital Employed (ROCE) |
|---|---|---|---|---|---|
| 14.87 | 6.61% | 230.00 | Nil | 6.12% | 20.17% |
Offer Objectives
The offer involves the sale of up to 14,233,964 Equity Shares by existing shareholders, namely International Finance Corporation, NYLIM Jacob Ballas India Fund III LLC, and Resurgence PE Investments Limited. The company aims to list its Equity Shares on the Stock Exchanges to enhance visibility and brand image.
Employee Stock Option Plan (ESOP) 2013: As of the DRHP date, the company has granted 1,445,937 options under ESOP 2013. The exercise price for outstanding options is ₹428 per share. In Fiscal Year 2021, 218,143 options were vested and 231,000 were forfeited/lapsed/cancelled. As of April 1, 2023, 271,500 options remained outstanding.
Offer Proceeds: The Selling Shareholders will receive the entire proceeds from the Offer, net of expenses and taxes. The Company will not receive any proceeds from the Offer.
Offer Expenses: Estimated expenses are ₹[●] million. These include fees for BRLMs, commissions, SCSBs, sponsor banks, legal counsels, registrar, auditors, advertising, and listing fees. The Selling Shareholders will bear all costs, reimbursing the Company pro-rata after filing the Draft Red Herring Prospectus.
For example, the Selling commission for applications made by RIBs using 3-in-1 accounts and Non -Institutional Bidders which are procured by them and submitted to SCSB for blocking or using 3 -in-1 accounts, would be as follows:
Portion for RIBs [●]% of the Amount Allotted* (plus applicable taxes)
Portion for Non -Institutional Bidders [●]% of the Amount Allotted* (plus applicable taxes)
Company Details
Address:
Fortis Hospital, Sector 62, Phase VIII, Mohali - 160 062, Punjab, India
Phone: 0124 -6261111
Email: [email protected]
Website: http://www.agilusdiagnostics.com
IPO Registrar Details
KFin Technologies Limited
Phone: +91 40 6716 2222, 18003094001
Email: [email protected]
Website: http://www.kfintech.com
Offer Prospectus & Documents
Lead Managers
- Icici Securities Limited
- Axis Capital Limited
- Citigroup Global Markets India Private Limited
